Announcement of Full-year Financial Results 2022/23 Coloplast delivered Q4 organic growth of 8% and 28% EBIT margin1). Reported revenue in DKK grew 3% to 6,226 million, impacted by unfavourable.
Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://investor.coloplast.com/investor-relations/financial-calendar-and-events/ Kind.
Coloplast has completed the acquisition of Kerecis, announced on July 7, 2023, after receiving approval from all relevant authorities and reaching a shareholder acceptance level of 100% The terms.
Major shareholder notification Reference is made to the press release issued by Coloplast A/S on 21 June 2023 regarding the intention of Coloplast A/S largest shareholders, Niels Peter.